18 Oct 2021
Leukaemia UK drives forward progress for leukaemia research through five new John Goldman Fellowships for 2021
Leukaemia UK today announced five new John Goldman Fellows for 2021, from across the UK, to accelerate progress and stop the disease devastating lives. Innovators in their fields, each of Leukaemia UK’s John Goldman Fellows will explore a new angle to treating leukaemia over the next two years.
Leukaemia remains one of the deadliest cancers, with an overall UK survival rate of just over 50 per cent (2013-2017). Treatments are harsh and are still lagging behind other cancers in their success rates. Leukaemia is the most common childhood cancer, with it accounting for 33 per cent of all cancers in the under 14s.
Fiona Hazell, Chief Executive of Leukaemia UK, said:
“Whilst blood cancer is the fifth most common cancer in the UK, it remains the third most deadly. Further research is vital to improve survival rates in leukaemia as well as the quality of life for those who receive this devastating diagnosis. Leukaemia UK’s John Goldman Fellowships are novel research projects which will help accelerate progress through the development of much needed new and better treatments for leukaemia and other blood cancers, helping save and improve the lives of those living with the disease.”
Based across the UK in Birmingham, London, Edinburgh, York and Oxford, the new Leukaemia UK John Goldman Fellows are embarking on research projects ranging from looking at how more targeted drug treatments can be developed to treat acute myeloid leukaemia (AML) patients, to looking at the behaviour of leukaemia-associated immune cells called macrophages in infant leukaemia to see if they have a significant role in the onset or progression of the disease.
Leukaemia UK’s John Goldman Fellows for 2021 are:
Dr Daniel Coleman of the University of Birmingham who will be . By targeting mutated RAS genes Dr Coleman hopes to block the pathway for leukaemia cells to grow and will identify further treatment targets to reduce the need for aggressive chemotherapy in vulnerable patients.
Dr Coleman said: “Acute myeloid leukaemia (AML) is a particularly aggressive blood cancer and most often affects elderly patients. It is frequently difficult to treat with aggressive chemotherapy as patients are often already quite frail. For this reason, it is important to develop treatments which target just the cancer cells and leave the healthy cells intact.”
Dr Pramila Krishnamurthy of King’s College Hospital and King’s College London will be using the fellowship to better understand why some leukaemia patients relapse following a stem cell transplant, and how donor lymphocyte infusion can help prevent this. Her fellowship is co-funded by Rosetrees Trust.
Dr Krishnamurthy said,“Over 50% of patients with acute leukaemias relapse after stem cell transplant, and once this occurs, the chance of cure is unlikely. Relapse can be prevented by infusing donor-derived immune cells after the transplant. During my John Goldman Fellowship I will explore the use of donor lymphocyte infusion to help correct defects in patients’ immune responses so that they are better able to fight their underlying cancer.”
Dr William Grey of the University of York will be , by targeting protein modifications and their breakdown.
Dr Grey said: “In this fellowship funded by Leukaemia UK I will investigate specific targeting of leukaemic stem cells, leveraging an Achilles heel in their protein turnover machinery. In combination with newly available medicines, I aim to improve treatment options for the most elderly and at-risk AML patients.”
Dr Mariani said: “Acute leukaemias, the most common in infants and children, are difficult to treat. Chemotherapy is only able to eradicate the disease in half of infant cases. There is a critical need to understand what happens in the early stages of leukaemia’s development to better target the progression of the disease.”
Dr Orlando said: “During my John Goldman Fellowship I will study a rare form of childhood cancer, juvenile myelomonocytic leukaemia (JMML), characterised by alterations in RAS genes within cells. No target treatment is currently available for this type of leukaemia, and the only curative option is bone marrow transplant. Even after transplant, 35% of patients relapse. By studying the molecular mechanisms behind RAS driven gene regulation, I hope that this research might lead to new targeted treatments being employed to improve patient outcome.”
You can read coverage of the story by Charity Today here.
11 January 2019
AML: What is the role of the GATA2 protein?
Dr Salima (Sarah) Nurmohamed, University of Oxford and John Goldman Fellow
4 April 2022
Leukaemia UK launches search for five new talented Trustees
We are looking for a talented and diverse set of Trustees to join our Board, and help guide the charity as we embark on an ambitious new strategy to accelerate progress in leukaemia research to stop leukaemia devastating lives.
17 October 2018
Come and celebrate the end of the ultra challenge season…
11 January 2019
GvHD: Finding a better treatment
Dr Antonio Galleu, King’s College London and John Goldman Fellow